Nevertheless, in our study, neither the TRPA1 blocker nor TRPV1 or TRPV2 antagonists reduced F4-SM or F5-SM activity, suggesting TRPA1, TRPV1, and TRPV2 are not involved in the cytotoxic activity of these compounds on GBM cells. This evidence concerns the gene TRPV2 and glioblastoma.